Novo Nordisk A/S (NVO) to Release Quarterly Earnings on Wednesday

Novo Nordisk A/S (NYSE:NVO) is projected to post its Q4 2025 results before the market opens on Wednesday, February 4th. Analysts expect Novo Nordisk A/S to post earnings of $0.90 per share and revenue of $11.9651 billion for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 7:00 AM ET.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The company had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. On average, analysts expect Novo Nordisk A/S to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $62.90 on Wednesday. The business’s 50-day moving average is $52.75 and its two-hundred day moving average is $54.50. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The company has a market capitalization of $280.86 billion, a P/E ratio of 18.29 and a beta of 0.66. Novo Nordisk A/S has a fifty-two week low of $43.08 and a fifty-two week high of $93.80.

Institutional Trading of Novo Nordisk A/S

Large investors have recently bought and sold shares of the company. Sunbelt Securities Inc. increased its stake in Novo Nordisk A/S by 58.7% during the 3rd quarter. Sunbelt Securities Inc. now owns 20,993 shares of the company’s stock worth $1,165,000 after buying an additional 7,764 shares during the period. Advisory Services Network LLC lifted its stake in shares of Novo Nordisk A/S by 12.1% in the third quarter. Advisory Services Network LLC now owns 98,850 shares of the company’s stock valued at $5,485,000 after buying an additional 10,642 shares during the period. Peloton Wealth Strategists raised its position in Novo Nordisk A/S by 39.5% in the 3rd quarter. Peloton Wealth Strategists now owns 36,880 shares of the company’s stock valued at $2,046,000 after purchasing an additional 10,450 shares during the last quarter. Saratoga Research & Investment Management boosted its stake in Novo Nordisk A/S by 22.5% in the 3rd quarter. Saratoga Research & Investment Management now owns 1,853,707 shares of the company’s stock worth $102,862,000 after purchasing an additional 341,030 shares during the period. Finally, Abel Hall LLC boosted its stake in shares of Novo Nordisk A/S by 27.8% during the 3rd quarter. Abel Hall LLC now owns 7,929 shares of the company’s stock worth $440,000 after acquiring an additional 1,724 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on NVO shares. Hsbc Global Res lowered Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 24th. Weiss Ratings reissued a “sell (d+)” rating on shares of Novo Nordisk A/S in a research note on Monday, December 29th. BMO Capital Markets set a $57.00 price objective on Novo Nordisk A/S in a research report on Monday. HSBC restated a “hold” rating and issued a $54.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 10th. Finally, Jefferies Financial Group began coverage on shares of Novo Nordisk A/S in a research report on Monday, October 27th. They issued an “underperform” rating for the company. One investment analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have given a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $57.79.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.